US3653836A - Reagent for determining blood sugar - Google Patents

Reagent for determining blood sugar Download PDF

Info

Publication number
US3653836A
US3653836A US66953A US3653836DA US3653836A US 3653836 A US3653836 A US 3653836A US 66953 A US66953 A US 66953A US 3653836D A US3653836D A US 3653836DA US 3653836 A US3653836 A US 3653836A
Authority
US
United States
Prior art keywords
percent
weight
reagent
blood sugar
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US66953A
Other languages
English (en)
Inventor
Wolfgang Gruher
Erich Bernt
August Wilhelm Wahlefeld
Werner Dollacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US3653836A publication Critical patent/US3653836A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose

Definitions

  • the present invention is concerned with a reagent for the determination of blood sugar by the o-toluidine method, which reagent does not contain glacial acetic acid.
  • isophthalic acid and terephthalic acid are useless for weight, based on total weight of composition.
  • the two above-mentioned glacial acetic acid-free reagents overcome the problem of malodor and also somewhat improve the sensitivity of the test.
  • This sensitivity is, in the case of the usual normal values for the blood sugar content in whole blood of 60 100 mg. percent, below the value ofE 0.100 at the measurement wavelength of 578 nm usually employed.
  • a further disadvantage of the two above-mentioned known reagents is the instability of the solvent mixture which is due to the content of readily volatile components.
  • the increased evaporation rate is of significance because the reagent must be heated for 8 minutes in a boiling waterbath for the development of the coloration.
  • the dissolved substances start to crystallize out.
  • phthalic acid is an outstanding catalyst for An especially preferred composition consists of 0.075 0.15 percent by weight thiourea, 20 25 percent by weight phthalic acid, 35 55 percent by weight dimethyl formamide, 20 40percent by weight ethylene glycol mono-lower alkyl ether and 7.5 10 percent by weight o-toluidine, based on total weight of composition.
  • lower alkly is to be understood to mean an alkyl radical containing up to six carbon atoms.
  • the reagent according to the present invention can contain up to about 5 percent water, without its usefulness being thereby impaired.
  • the reagent according to the present invention does not result in any unpleasant smell nor is there any danger of a loss of solvent when heating in order to bring about formation of the colored material.
  • the reagent is colorless to pale yellow in color and the viscosity is low so that there is no impairment of the pipetting due to air bubbles or after-runnings.
  • the reagent is also storage stable although, in the case of comparatively long periods of storage at an elevated temperature (33 C. an intensification of the yellow color can occur. However, this influences neither the measurement sensitivity to any considerable extent nor the stability of the color formed.
  • FIG. 1 is a plot extinction values against glucose concentration
  • the superior sensitivity of the reagent according to the present invention is of great practical importance since it is hereby possible, even in the cases of hypoglycaemia, as well as in the cases in which only very little blood is available, i.e., in the case of blood sugar measurement values of 30 50 mg. percent, to obtain extinctions of the order of 0.050 to 0.082 at 578 nm, measured against a blank, so that errors of measurement in the reading off of the photometer are very considerably reduced.
  • a further advantage of the reagent according to the present invention lies in the fact that in the region of the especially preferred composition, it represents a so-called optimum composition. This means that all individual components of the mixture are present in the concentration in which the sensitivity, the period of incubation of the test and the stability of the resultant color have their maxima and a slight alteration of the conditions does not cause any significant differences in the course of the test or in the measurement operation. The working errors are, therefore, in the case of this composition, extremely low.
  • the color which arises in the case of the o-toluidine reaction is, in principle, unstable. It is assumed that an unknown secondary reaction follows by means of which the extinction at 640 nm, the maximum, and at the measurement wavelength of 578 nm, decreases in the course of time. This instability of the color is reduced in the case of the reagent according to the had at ambient temperature at the end of the incubation.
  • glycollic acid reagent was used as comparison reagent.
  • superior stability of the reagent according to the present invention This improvement represents an important advantage when a large series of tests are to be measured one after the other.
  • a further advantage of the reagent according to the present invention lies in the fact that the stability is independent of the glucose concentration in the sample. The possibilities of error of the method are hereby minimized.
  • a further advantage of the reagent according to the present invention is its cheapness.
  • the cost of phthalic acid is only about one-ninth of the cost of glycollic acid.
  • Example 1 ml. ethylene glycol monoethyl ether were then added thereto and finally 18.0 ml. o-toluidine was stirred in.
  • 0.1 ml. of blood was pipetted into 1.0 ml. 3 percent trichloroacetic acid, mixed and, after standing for a few minutes, centrifuged.
  • Areagent composition for determination of blood sugar which composition comprises o-toluidine, thiourea, an ethylene glycol mono-lower alkyl ether, phthalic acid, and dimethyl formamide as a solubilizing agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US66953A 1969-08-27 1970-08-26 Reagent for determining blood sugar Expired - Lifetime US3653836A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19691943580 DE1943580B2 (de) 1969-08-27 1969-08-27 Reagens zur blutzuckerbestimmung

Publications (1)

Publication Number Publication Date
US3653836A true US3653836A (en) 1972-04-04

Family

ID=5743926

Family Applications (1)

Application Number Title Priority Date Filing Date
US66953A Expired - Lifetime US3653836A (en) 1969-08-27 1970-08-26 Reagent for determining blood sugar

Country Status (11)

Country Link
US (1) US3653836A (de)
JP (1) JPS494356B1 (de)
BR (1) BR7020400D0 (de)
CH (1) CH538118A (de)
DE (1) DE1943580B2 (de)
FR (1) FR2059346A5 (de)
GB (1) GB1261477A (de)
IL (1) IL34773A (de)
NL (1) NL7011423A (de)
SE (1) SE360176B (de)
ZA (1) ZA705187B (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853473A (en) * 1972-08-30 1974-12-10 Medico Electronic Inc Reagent and method for urea determination
US3853469A (en) * 1972-08-30 1974-12-10 Medico Electronic Inc Reagent and method for phosphorus determination
WO1986003585A1 (en) * 1984-12-11 1986-06-19 Lawrence Paul J Fecal occult blood test reagents and methods
US4818702A (en) * 1986-06-02 1989-04-04 Litmus Concepts, Inc. Fecal occult blood test reagent
US5426032A (en) * 1986-08-13 1995-06-20 Lifescan, Inc. No-wipe whole blood glucose test strip
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1098808A (en) * 1977-03-14 1981-04-07 Charles T. W. Lam Test composition and device for determining peroxidatively active substances

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453180A (en) * 1965-08-02 1969-07-01 Miles Lab Test article

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453180A (en) * 1965-08-02 1969-07-01 Miles Lab Test article

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chem. Abs. 67: 50965y (1967). *
Chem. Abs. 69: 103698n (1968). *
Chem. Abs. 69: 93549y (1968). *
Chem. Abs. 71: 10133a (1969). *
Chem. Abs. 71: 27817z (1969). *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853473A (en) * 1972-08-30 1974-12-10 Medico Electronic Inc Reagent and method for urea determination
US3853469A (en) * 1972-08-30 1974-12-10 Medico Electronic Inc Reagent and method for phosphorus determination
WO1986003585A1 (en) * 1984-12-11 1986-06-19 Lawrence Paul J Fecal occult blood test reagents and methods
US4818702A (en) * 1986-06-02 1989-04-04 Litmus Concepts, Inc. Fecal occult blood test reagent
US20030054427A1 (en) * 1986-08-13 2003-03-20 Roger Phillips Minimum procedure system for the determination of analytes
US6858401B2 (en) 1986-08-13 2005-02-22 Lifescan, Inc. Minimum procedure system for the determination of analytes
US5843692A (en) * 1986-08-13 1998-12-01 Lifescan, Inc. Automatic initiation of a time interval for measuring glucose concentration in a sample of whole blood
US6268162B1 (en) 1986-08-13 2001-07-31 Lifescan, Inc. Reflectance measurement of analyte concentration with automatic initiation of timing
US6887426B2 (en) 1986-08-13 2005-05-03 Roger Phillips Reagents test strip adapted for receiving an unmeasured sample while in use in an apparatus
US6881550B2 (en) 1986-08-13 2005-04-19 Roger Phillips Method for the determination of glucose employing an apparatus emplaced matrix
US5426032A (en) * 1986-08-13 1995-06-20 Lifescan, Inc. No-wipe whole blood glucose test strip
US5563042A (en) * 1986-08-13 1996-10-08 Lifescan, Inc. Whole blood glucose test strip
US20030073152A1 (en) * 1986-08-13 2003-04-17 Roger Phillips Minimum procedure system for the determination of analytes
US20030073153A1 (en) * 1986-08-13 2003-04-17 Roger Phillips Minimum procedure system for the determination of analytes
US20030073151A1 (en) * 1986-08-13 2003-04-17 Roger Phillips Minimum procedure system
US6821483B2 (en) 1986-08-13 2004-11-23 Lifescan, Inc. Reagents test strip with alignment notch
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6979571B2 (en) 1999-11-24 2005-12-27 Home Diagnostics, Inc. Method of using a protective test strip platform for optical meter apparatus
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
US7390665B2 (en) 2001-02-28 2008-06-24 Gilmour Steven B Distinguishing test types through spectral analysis

Also Published As

Publication number Publication date
DE1943580A1 (de) 1971-04-08
FR2059346A5 (de) 1971-05-28
SE360176B (de) 1973-09-17
BR7020400D0 (pt) 1973-03-20
IL34773A (en) 1973-05-31
ZA705187B (en) 1971-05-27
JPS494356B1 (de) 1974-01-31
NL7011423A (de) 1971-03-02
GB1261477A (en) 1972-01-26
DE1943580B2 (de) 1971-08-05
CH538118A (de) 1973-06-15
IL34773A0 (en) 1970-08-19

Similar Documents

Publication Publication Date Title
Watson A simple method for the determination of serum cholesterol
Lowry [17] Micromethods for the assay of enzymes
US5776719A (en) Diagnostic compositions and devices utilizing same
EP0102504B1 (de) Für einen breiten Bereich geeignete, ascorbat-unempfindliche Zusammensetzung zur Prüfung auf Glucose, Prüfmittel und Methode
US3653836A (en) Reagent for determining blood sugar
US3595755A (en) Detection of hydrogen peroxide
US4897346A (en) Stabilized liquid enzyme composition for glucose determination
US3533749A (en) Method for the determination of total albumin
JP3131924B2 (ja) 検体測定のための改良法及び試薬
US4143080A (en) Method and reagent for the assay of hydroperoxide
US3862012A (en) Quantitative determination of uric acid
Slater [3] Manometric methods and phosphate determination
Momose et al. Determination of Total Cholesterol in Blood Serum with Perchloric Acid-Phosphoric Acid-Ferric Chloride Reagent.
US4511651A (en) Reagent composition and assay for the determination of γ-glutamyltransferase activity
JPS59183698A (ja) 基質又は酵素活性の定量方法
ES2227796T3 (es) Metodos y reactivos para determinar cuantitativamente acido ascorbico.
EP0044432B1 (de) Stabilisierte enzymatische Lösungen und Verfahren zum Bestimmen von Gesamtcholesterin im menschlichen Serum
Asp Improved method for the assay of phenylglycosidase activity with a 4-aminoantipyrine reagent
US3778384A (en) Diagnostic composition for the quantitative determination of glucose
EP0586397A4 (de) Verbessertes verfahren und mittel zur bestimmung eines analyten.
US3558516A (en) Cholesterol determination reagent of ferric perchlorate,sulfuric acid and ethyl acetate
US4142938A (en) Determination of triglycerides and glycerol
Hoch et al. The Determination of Iodine in Biologic Material
Björkhem et al. A simple, fully enzymic bioluminescent assay for triglycerides in serum.
Yip et al. Interaction of tetraiodofluorescein with yeast hexokinase.